The federal district court in Wilmington, Delaware, did not err in finding that several claims of a patent for preparing a stable formulation of the antibiotic compound ertapenem owned by Merck Sharp & Dohme were invalid as obvious, the U.S. Court of Appeals for the Federal Circuit has held. Substantial record evidence supported the district court’s conclusion that the claimed process would have been obvious at the time the invention was made. Merck’s objective evidence of obviousness—commercial success and copying by others—was insufficient to overcome the “strong prima facie case of obviousness.” Circuit Judge Pauline Newman filed a dissenting opinion (Merck Sharp & Dohme Corp. v. Hospira, Inc., October 26, 2017, Lourie, A.).

A full summary of this case has been published on Kluwer IP Law.



To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law

The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

Kluwer IP Law
This page as PDF